Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “New York”

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaActive Not Recruiting
NCT04759586Phase 3Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Primary Mediastinal Large B-Cell Lymphoma
United States, Australia, Canada, Puerto Rico
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruiting
NCT04269902Phase 3Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
United States, Canada
A Study of GEN1106 in Participants With Solid TumorsRecruiting
NCT07416123Phase 1Updated Sep 10, 2026
Sponsor: Genmab
Solid Tumors · Urothelial Carcinoma
United States, Japan, Spain
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMDRecruiting
NCT06659445Phase 2Updated Sep 10, 2026
Sponsor: ONL Therapeutics
Geographic Atrophy (GA) · Age - Related Macular Degeneration (AMD)
United States, Austria, Canada, Czechia, Germany +7 more
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain MetastasesCompleted
NCT02360215Phase 3Updated Sep 10, 2026
Sponsor: NRG Oncology
Cognitive Impairment · Metastatic Malignant Neoplasm in the Brain · Solid Neoplasm
United States, Canada
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)Recruiting
NCT05099003Phase 1, Phase 2Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Malignant Glioma
United States, Australia, Canada, New Zealand
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyActive Not Recruiting
NCT05444257Phase 3Updated Sep 10, 2026
Sponsor: Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
United States, Australia, Austria, Belgium, Canada +18 more
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)Completed
NCT02910583Phase 2Updated Sep 10, 2026
Sponsor: Pharmacyclics LLC.
Leukemia · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
United States, Australia, Italy, New Zealand, Poland +1 more
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases NetworkRecruiting
NCT02450851N/AUpdated Sep 10, 2026
Sponsor: National Human Genome Research Institute (NHGRI)
Genetic Disease
United States
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerRecruiting
NCT05946213Phase 3Updated Sep 10, 2026
Sponsor: NRG Oncology
Prostate Adenocarcinoma · Stage III Prostate Cancer AJCC v8 · Stage IVA Prostate Cancer AJCC v8
United States, Canada, Hong Kong, Switzerland
BOND: Direct Breastfeeding to Enhance Maternal and Infant Health in Congenital Heart DiseaseRecruiting
NCT07582848NAUpdated Sep 10, 2026
Sponsor: Carelon Research
Congenital Heart Disease (CHD)
United States
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid TumorsRecruiting
NCT07730021Phase 1, Phase 2Updated Sep 10, 2026
Sponsor: Astellas Pharma Global Development, Inc.
Locally Advanced or Metastatic Solid Tumors
United States
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruiting
NCT06058377Phase 3Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · HER2-Negative Breast Carcinoma · Hormone Receptor-Positive Breast Carcinoma
United States, Puerto Rico
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)Completed
NCT03694275Phase 2Updated Sep 10, 2026
Sponsor: Takeda
15q Duplication Syndrome · CDKL5 Deficiency Disease
United States
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)Recruiting
NCT05947955Phase 2Updated Sep 10, 2026
Sponsor: BioAegis Therapeutics Inc.
Acute Respiratory Distress Syndrome · Infections
United States, Belgium, Bulgaria, Canada, Czechia +8 more
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruiting
NCT05987241Phase 2, Phase 3Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Renal Pelvis Urothelial Carcinoma · Muscle Invasive Ureter Urothelial Carcinoma · Muscle Invasive Urethral Urothelial Carcinoma
United States, Canada
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)Recruiting
NCT06917911Phase 2Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Core Binding Factor Acute Myeloid Leukemia
United States
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisRecruiting
NCT05828069Phase 2Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Recurrent Langerhans Cell Histiocytosis · Refractory Langerhans Cell Histiocytosis
United States, Australia, Canada
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to TrikaftaCompleted
NCT07108153Phase 2Updated Sep 10, 2026
Sponsor: Sionna Therapeutics Inc.
Cystic Fibrosis (CF)
United States, Australia
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruiting
NCT06317662Phase 2Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Acute Leukemia of Ambiguous Lineage · B Acute Lymphoblastic Leukemia
United States, Puerto Rico
Electrophysiologic Sleep Phenotyping and Sleep-Dependent Neuro-maturation in Clinical and Healthy Pediatric PopulationsRecruiting
NCT04639830N/AUpdated Sep 10, 2026
Sponsor: National Institute of Mental Health (NIMH)
Healthy Children · Children With Neurodevelopmental Disorders · Children With Neuropsychiatric Disorders · Children With Behavioral Syndromes
United States
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and OsteoarthritisRecruiting
NCT07339111Phase 3Updated Sep 10, 2026
Sponsor: Medipost, Inc.
Knee Cartilage Defects
United States
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsRecruiting
NCT06008197Phase 3Updated Sep 10, 2026
Sponsor: Colorado Prevention Center
Heart Failure · Acute Heart Failure
United States, Argentina, Australia, Brazil, Bulgaria +21 more
Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD)Recruiting
NCT07582861NAUpdated Sep 10, 2026
Sponsor: Carelon Research
Congenital Heart Disease (CHD)
United States
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationTerminated
NCT05636176Phase 3Updated Sep 10, 2026
Sponsor: Novo Nordisk A/S
Heart Failure
United States, Argentina, Australia, Austria, Belgium +41 more

Previous page Next page